Panacea Stars: Catalysing Success in Science
Since our inception in Oxford in 2015, Panacea has been pivotal in the formation of over 450 companies, propelling our top 60 to a combined valuation of approximately £1.5Bn. Our unique blend of comprehensive R&D, commercialisation support, and essential funding transforms promising ideas into viable, successful enterprises.
Exclusive Support and Investment Opportunities
We’re committed to advancing science and health-related innovations, from early-stage ideas to ready-for-market products. Our equity-free, 8-week Develop programme is dedicated to empowering founders to de-risk and refine their ideas. It offers significant benefits including wide-ranging support in scientific, clinical, financial, and legal aspects; tailored mentorship; access to industry leaders; guided experimentation; and exposure to a community of like-minded innovators. The standout companies gain priority access to pre-seed and seed investments through Panacea Ventures.
We welcome ideas at all stages of development that have the potential to impact human health – anything from therapeutics and diagnostics to medical devices, apps and research platforms. We have previously selected finalists with ideas ranging from the very early stage to patent-protected, as well as university start-ups to potential spin-outs.
Distinguishing Panacea Stars is our robust network of over 200 C-suite mentors from leading entities like AstraZeneca, GSK, AbbVie, Novo Nordisk, IBM, Bio-Rad, Taylor Wessing, J A Kemp, and McKinsey & Co. These mentors, poised to join company boards, along with support from esteemed funding bodies such as Cancer Research UK and the British Heart Foundation, significantly amplify our participants’ development and success.
Join Our Develop Spring/Summer 2025 Cohort
We invite the next wave of innovators to the Spring/Summer 2025 cohort of the Develop programme.
| Application Deadline |
28/02/2025 |
| Event type |
Programme |
| Booking required? |
Apply Here |
